Researchers at Brigham and Women's Hospital (BWH), affiliate to Harvard Medical School, are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment. Supramolecular chemistry is the development of complex chemical systems using molecular building blocks. The researchers utilized such methods to create nanoparticles that significantly enhanced antitumor activity with decreased toxicity in breast and ovarian cancer models
"This work is effectively moving beyond using nanotechnology as drug 'delivery' vehicles to reengineering drugs themselves so that they become nanomedicines." said Shiladitya Sengupta, PhD, MSc, BWH associate bioengineer, and senior study author .